Cyclobutapyridin | 56911-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Cyclobutapyridin
• 英文别名: 2,3-Cyclobutenopyridine；2-azabicyclo[4.2.0]octa-1(6),2,4-triene
• CAS: 56911-25-2
• 化学式: C₇H₇N
• 分子量: 105.139
• InChiKey: ZTHQKDZTNXUQJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Cyclobutapyridin 生成 2-azabicyclo[4.2.0]octane
  参考文献：
  名称：

  THUMMEL R. P.; KOHLI D. K., D1J. ORG. CHEM., 1978, 43, NO 25, 4882-4884

  摘要：

  DOI：
• 作为产物：
  描述：

  Propargyl-4-pyridylether 以7%的产率得到
  参考文献：
  名称：

  RIEMANN J. M.; TRAHANOVSKY W. S., TETRAHEDRON LETT. , 1977, NO 22, 1867-1870

  摘要：

  DOI：

文献信息

• MAX BINDERS AS MYC MODULATORS AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20170233405A1

  公开（公告）日：2017-08-17

  The present disclosure provides compounds of Formula (I′), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.

  本公开提供了Formula (I′)、Formula (I)、Formula (II)、Formula (II-A)、Formula (III)和Formula (IV)的化合物。本文描述的化合物是MAX结合蛋白和/或Myc、Mad或Mxi1的调节剂（例如，Myc、Mad或Mxi1的抑制剂），可能在治疗与Myc相关的疾病的患者中有用，例如增殖性疾病（例如癌症）。本公开还提供了包括上述化合物的药物组合物和试剂盒，以及使用这些化合物、组合物和试剂盒的方法和用途。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2021138434A1

  公开（公告）日：2021-07-08

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及化学实体（例如，一种化合物或药用可接受盐，和/或水合物，和/或共晶体，和/或该化合物的药物组合），可抑制（例如，拮抗）干扰素基因激活器（STING）。所述化学实体可用于治疗条件、疾病或障碍，其中增加（例如，过度）STING激活（例如，STING信号传导）对主体（例如，人类）的病理和/或症状和/或病情进展有贡献（例如，癌症）。本公开还涉及含有相同化学实体的组合物，以及使用和制备这些组合物的方法。
• CHAIN MULTIYNE COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF
  申请人：Xiamen University

  公开号：US20180065908A1

  公开（公告）日：2018-03-08

  The present invention relates to fields of organic chemistry and organometallic chemistry. The present invention discloses a chain multiyne compound, a preparation method thereof and an application in synthesizing a fused-ring metallacyclic compound. A structure of the chain multiyne compound in the present invention is shown as Formula I below. The present invention also provides a preparation method of the chain multiyne compound and an application thereof in a synthesis of a fused-ring metallacyclic compound. The chain multiyne compound disclosed in the present invention has multiple functional groups and the structure of the chain multiyne compound is adjustable. The chain multiyne compound can also be used to synthesize the fused-ring metallacyclic compound efficiently. The preparation method of the chain multiyne compound disclosed in the present invention is simple, which can be used to prepare the chain multiyne compound rapidly and efficiently.

  本发明涉及有机化学和有机金属化学领域。本发明公开了一种链状多炔化合物，其制备方法及在合成融环金属环化合物中的应用。本发明中的链状多炔化合物的结构如下式I所示。本发明还提供了链状多炔化合物的制备方法及其在合成融环金属环化合物中的应用。本发明公开的链状多炔化合物具有多个功能基团，其结构可调整。链状多炔化合物还可用于高效合成融环金属环化合物。本发明公开的链状多炔化合物的制备方法简单，可用于快速高效地制备链状多炔化合物。
• POLYMERIC CHARGE TRANSFER LAYER AND ORGANIC ELECTRONIC DEVICE CONTAINING SAME
  申请人：Dow Global Technologies LLC

  公开号：US20180212180A1

  公开（公告）日：2018-07-26

  The present invention provides a polymeric charge transfer layer composition comprising a polymer comprising, as polymerized units, at least one Monomer A and at least one Monomer B. It further provides an organic light emitting device and an organic electronic device comprising the polymeric charge transfer layer.

  本发明提供了一种聚合物电荷转移层组成物，其包括聚合物，该聚合物包括至少一个单体A和至少一个单体B作为聚合单元。本发明还提供了一种有机发光器件和有机电子器件，其中包括聚合物电荷转移层。
• Novel piperidine derivative
  申请人：Ohtake Norikazu

  公开号：US20070105901A1

  公开（公告）日：2007-05-10

  Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X 1 and X 2 independently represent a nitrogen atom or CH; Y represents a specific group; X 3 represents O s —(CH 2 ) m ; R 1 and R 2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

  本发明提供了一种组胺H3受体拮抗剂；以及预防和/或治疗代谢系统疾病，例如肥胖症、糖尿病、激素分泌障碍、高脂血症、痛风、脂肪肝、循环系统疾病，例如心绞痛、急性/充血性心力衰竭、心肌梗塞、冠状动脉硬化、高血压、肾病、睡眠障碍以及伴随着睡眠障碍的各种疾病，例如特发性嗜睡症、反复性嗜睡症、真性嗜睡症、嗜睡症、睡眠周期性运动障碍、睡眠呼吸暂停综合征、昼夜节律障碍、慢性疲劳综合征、REM睡眠障碍、老年失眠、夜班工人睡眠不卫生、特发性失眠、反复性失眠、真性失眠、电解质代谢障碍，以及中枢和外周神经系统疾病，例如贪食症、情绪障碍、忧郁症、焦虑症、癫痫、谵妄、痴呆、精神分裂症、注意力缺陷/多动障碍、记忆障碍、阿尔茨海默病、帕金森病、睡眠障碍、认知障碍、运动障碍、感觉异常、嗅觉障碍、癫痫、吗啡耐受、麻醉剂依赖、酒精依赖等的预防和/或治疗剂。该组胺H3受体拮抗剂包括式（I）的哌啶衍生物化合物[其中X1和X2独立地表示氮原子或CH；Y表示特定基团；X3表示Os—（CH2）m；R1和R2独立地表示氢原子、卤素原子、线性或支链低碳基、低碳氧基或2或3个氟原子取代的乙酰基；s为0或1；m是一个使（m+s）为0或1至4的整数]或其药学上可接受的盐。